However, such studies (1) only compared SGLT-2 inhibitors to a single class of other anti-diabetes medication or a reference group that consists of multiple classes of agents, and (2) only investigated into either clinical outcome(s) or cost outcome(s)4,5,9,10. The gene discussed is SLC5A2; the disease is diabetes mellitus.